HRP20180301T1 - Postupci liječenja psorijaze uporabom il-17 antagonista - Google Patents

Postupci liječenja psorijaze uporabom il-17 antagonista Download PDF

Info

Publication number
HRP20180301T1
HRP20180301T1 HRP20180301TT HRP20180301T HRP20180301T1 HR P20180301 T1 HRP20180301 T1 HR P20180301T1 HR P20180301T T HRP20180301T T HR P20180301TT HR P20180301 T HRP20180301 T HR P20180301T HR P20180301 T1 HRP20180301 T1 HR P20180301T1
Authority
HR
Croatia
Prior art keywords
secukinumab
patient
psoriasis
treatment
use according
Prior art date
Application number
HRP20180301TT
Other languages
English (en)
Croatian (hr)
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180301(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20180301T1 publication Critical patent/HRP20180301T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20180301TT 2010-10-08 2011-10-07 Postupci liječenja psorijaze uporabom il-17 antagonista HRP20180301T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
EP11764764.4A EP2625199B1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (1)

Publication Number Publication Date
HRP20180301T1 true HRP20180301T1 (hr) 2018-03-23

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180301TT HRP20180301T1 (hr) 2010-10-08 2011-10-07 Postupci liječenja psorijaze uporabom il-17 antagonista

Country Status (28)

Country Link
US (9) US9717791B2 (OSRAM)
EP (4) EP3792281A1 (OSRAM)
JP (2) JP5537740B2 (OSRAM)
KR (3) KR20150018595A (OSRAM)
CN (2) CN103154031A (OSRAM)
AU (1) AU2011311482B2 (OSRAM)
BR (1) BR112013008501A2 (OSRAM)
CA (1) CA2813900C (OSRAM)
CL (1) CL2013000930A1 (OSRAM)
CY (1) CY1119942T1 (OSRAM)
DK (1) DK2625199T3 (OSRAM)
ES (1) ES2660770T3 (OSRAM)
HK (1) HK1247932A1 (OSRAM)
HR (1) HRP20180301T1 (OSRAM)
HU (1) HUE038334T2 (OSRAM)
IL (1) IL225310A (OSRAM)
LT (1) LT2625199T (OSRAM)
MA (1) MA34646B1 (OSRAM)
MX (1) MX356279B (OSRAM)
NO (1) NO2625199T3 (OSRAM)
PH (1) PH12013500660B1 (OSRAM)
PL (1) PL2625199T3 (OSRAM)
PT (1) PT2625199T (OSRAM)
RU (2) RU2665954C1 (OSRAM)
SG (1) SG188979A1 (OSRAM)
SI (1) SI2625199T1 (OSRAM)
TW (2) TWI564022B (OSRAM)
WO (1) WO2012045848A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
HUE044038T2 (hu) 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2012341081B2 (en) * 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
AU2014228553B2 (en) * 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
US20160060337A1 (en) * 2013-03-15 2016-03-03 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
JP6596014B2 (ja) * 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
JP6663910B2 (ja) * 2014-08-26 2020-03-13 アムジェン ケー・エー，インコーポレイテッド 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法
KR20230170796A (ko) * 2014-09-10 2023-12-19 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
MY206805A (en) * 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
ES2992409T3 (es) * 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
WO2018096467A1 (en) * 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2009507023A (ja) * 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
ES2672221T3 (es) * 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
UA103499C2 (ru) * 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение

Also Published As

Publication number Publication date
US20230321231A1 (en) 2023-10-12
CA2813900C (en) 2017-01-10
HK1247932A1 (en) 2018-10-05
EP2625199A1 (en) 2013-08-14
JP5537740B2 (ja) 2014-07-02
PT2625199T (pt) 2018-02-28
EP3792281A1 (en) 2021-03-17
PH12013500660A1 (en) 2013-05-20
NO2625199T3 (OSRAM) 2018-04-21
US20170304439A1 (en) 2017-10-26
KR20150018595A (ko) 2015-02-23
US9717791B2 (en) 2017-08-01
PH12013500660B1 (en) 2017-10-27
JP2014114288A (ja) 2014-06-26
HUE038334T2 (hu) 2018-10-29
ES2660770T3 (es) 2018-03-26
CY1119942T1 (el) 2018-12-12
RU2665954C1 (ru) 2018-09-05
KR101620771B1 (ko) 2016-05-12
CL2013000930A1 (es) 2014-03-28
US20200171147A1 (en) 2020-06-04
TW201630625A (zh) 2016-09-01
TW201216984A (en) 2012-05-01
JP2013543501A (ja) 2013-12-05
WO2012045848A1 (en) 2012-04-12
EP4137514A1 (en) 2023-02-22
MX356279B (es) 2018-05-22
EP3299390A1 (en) 2018-03-28
US20250161445A1 (en) 2025-05-22
US10583190B2 (en) 2020-03-10
DK2625199T3 (en) 2018-02-26
IL225310A0 (en) 2013-06-27
CN107029234A (zh) 2017-08-11
EP2625199B1 (en) 2017-11-22
LT2625199T (lt) 2018-03-12
BR112013008501A2 (pt) 2016-08-16
MX2013003916A (es) 2013-06-03
CN103154031A (zh) 2013-06-12
US20250161443A1 (en) 2025-05-22
US20210113688A1 (en) 2021-04-22
US11534490B2 (en) 2022-12-27
CA2813900A1 (en) 2012-04-12
RU2013120957A (ru) 2014-11-20
SI2625199T1 (en) 2018-03-30
KR20140097566A (ko) 2014-08-06
US20250161444A1 (en) 2025-05-22
PL2625199T3 (pl) 2018-04-30
IL225310A (en) 2016-10-31
TWI564022B (zh) 2017-01-01
RU2591083C2 (ru) 2016-07-10
AU2011311482A1 (en) 2013-04-04
US20130202610A1 (en) 2013-08-08
MA34646B1 (fr) 2013-11-02
TWI548419B (zh) 2016-09-11
US20210162044A1 (en) 2021-06-03
KR20130110179A (ko) 2013-10-08
SG188979A1 (en) 2013-05-31
AU2011311482B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
HRP20180301T1 (hr) Postupci liječenja psorijaze uporabom il-17 antagonista
HRP20191162T1 (hr) Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela
JP2012180381A5 (OSRAM)
BRPI0719009B8 (pt) mecanismo de dosagem e acionamento destinado a dispositivos de liberação de fármacos
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
NO20092323L (no) Doserings- og drivmekanisme for legemiddelleveringsanordning
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CY1124734T1 (el) Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
MX390570B (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
MX386380B (es) Forma de dosis de disolución rápida de vacuna oral que usa almidón.
HRP20180468T1 (hr) Novi derivat analoga inzulina
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
CY1120176T1 (el) Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
HRP20250052T1 (hr) Postupak liječenja multiple skleroze
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.
HK1244231A1 (zh) 使用hcg治疗慢性疼痛的方法和治疗
HRP20160811T1 (hr) Upotreba odiparcila u liječenju mukopolisaharidoze
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
UA115803U (xx) Спосіб лікування вертеброгенних радикулопатій